Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

Asset management firm Bitwise expects 2026 to be a breakout year for crypto, with Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH), and Solana (CRYPTO: SOL) all pushing to new all-time highs as ...

Bitwise is predicting that bitcoin will break from its historic four-year cycle and reach new highs in 2026. Asset manager Bitwise released a new report that argues that bitcoin is poised to break ...

The New York Giants execute a savvy trade-down from No. 2 overall, leveraging the premium value of their pick amid a quarterback frenzy, in the latest mock draft from The Athletic's Dane Brugler. With ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Vanguard will now allow investors to trade crypto ETFs on its brokerage platform. A key banking regulator spoke to members of the House Financial Services Committee about stablecoins. The newly ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

Solana (SOL) ETFs recorded 19 consecutive days of inflows totaling $476M since launching on October 28. Bitwise’s BSOL captured 89% of Solana ETF inflows at $424M by staking all holdings and charging ...

Prosecutors and defense negotiate a plea deal for Hardcastle in Bitwise fraud case. Hardcastle faces up to 20 years per wire-fraud count and $250,000 fines. Scheme involved $20 million hard-money ...

Fund provides exposure to the third-largest crypto asset, known for its 13-year track record and goal of disrupting the $250 trillion market for cross-border payments. "In 2025, we're watching digital ...